###### Strengths and limitations of this study

-   To our knowledge, this is the largest literature review and pooling analysis comparing treatment effects between blinded independent central review and local assessment in phase III randomised controlled trials on solid tumours.

-   We performed an exhaustive literature search to include all potential studies fulfilling the inclusion criteria.

-   We carefully extracted the data based on the independent and double-blind principle, in order to guarantee the accuracy of the data applied for further analysis.

-   Compared with our study-level analysis, the analysis using individual patients' data could be more robust.

-   For using trial data of both blinded independent central review and local assessment, the findings and conclusion of this research may not be generalisable for all phase III oncological randomised controlled trials, because the situation of either assessment could be unknown when trials did not implement or report both central and local assessments.

Introduction {#s1}
============

In phase III randomised controlled trials (RCTs), response-related or progression-related endpoints like objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and time to progression (TTP) are key for reflecting treatment effects of the experimental arm and the control arm for patients with advanced solid tumour.[@R1] During trials, determination of tumour response should be assessed with accuracy, which is the prerequisite of implementation with standardised response assessment criteria (eg, Response Evaluation Criteria in Solid Tumors (RECIST) and WHO) as well.

Unlike overall survival, these endpoints assessed by local investigators are more influenced by subjective factors, including variability during tumour measurement, target lesion selection, failure to diagnose new lesions and different interpretations of non-target or immeasurable lesions.[@R4] In open-label trials, the knowledge of investigators regarding treatment assignment could influence their assessment. Even in some double-blind trials, the investigators' knowledge may not be completely eliminated due to the adverse effects; for example, the investigators might be able to tell which treatments are assigned for their patients according to the different manifestations of treatments' adverse effects.[@R5]

Treatment effect is one of the main results considered for drug approval. If aforementioned subjective factors impact the assessment for trial endpoints, the subsequent result will overestimate or underestimate the true effect of treatments, which is called systematic bias.[@R6] In order to detect potential bias from local investigators, blinded independent central review is requested by the regulatory authorities (eg, the US Food and Drug Administration (FDA)). During its implementation, all imaging examinations are reviewed by independent radiologists who are blinded to patients' treatment assignments and clinical information.[@R7] However, this mechanism has some drawbacks. It increases the burden of time and expenditure on trials. Additionally, it may introduce missing data, information censoring and the neglect of symptomatic progression. These factors could result in different discrepancy rates of central and local assessments and sometimes among central reviewers themselves, which impacts treatment effects and may even cause potential bias.[@R4]

Given the pros and cons of assessment by central reviewers, the FDA Oncology Drugs Advisory Committee discussed how to design a reliable assessment strategy for clinical trials with central review: if there is no strong evidence indicating systematic bias from two assessments, a sample-based central review could be considered in future usage instead of the complete assessment for all patients in the trials.[@R9] This strategy may effectively reduce the complexity and implementation burden, without compromising the reliability of the RCTs.[@R9]

Accordingly, in order to understand the reliability of local assessment, as well as the necessity of central review, we conducted this literature review and analyses in order to investigate whether systematic bias existed in previous phase III RCTs on solid tumours.

Method {#s2}
======

Search strategy and study selection {#s2a}
-----------------------------------

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement,[@R10] a PubMed search was conducted by JRZ using the dates of 1 January 2010 to 30 June 2017. The search strategy is shown in online [supplementary etable 1](#SP7){ref-type="supplementary-material"}. Inappropriate articles such as reviews, systematic reviews and/or meta analyses, guidelines and commentaries were excluded.
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Eligible trials were those directly evaluating therapeutic efficacy of anticancer agents in phase III RCTs for patients with advanced solid tumour; additionally, the imaging assessment for tumour response or progression was conducted by both central reviewers and local investigators. As some authors reported their data in more than one article, we used the name and/or National Clinical Trial (NCT) number of eligible RCTs as search terms to re-search PubMed (without the time interval limitation), to find out if there were more available articles on those RCTs. Endnote X7 (Thomson Reuters, New York City, New York, USA) was used in the above process.

Data extraction {#s2b}
---------------

The process of data extraction was carried out independently and double-blindly by three reviewers (JRZ with YYZ and SYT; in blocks of 50 articles allocated at random; discrepancies were resolved by WHL). To ensure consistency between reviewers, we used the same data extraction form, piloted the data extraction by using a sample of 16 included trials and had discussions before and during the extraction process to confer how to properly extract and interpret the data.

The following characteristics of each trial were extracted: author, year, NCT number, funding source (pharmaceutical or academic), mask (open label, single blind or double blind), region (global or intracontinental), tumour type (eg, breast cancer, ovarian cancer, melanoma), study design (superiority, non-inferiority or hybrid; hybrid design includes the design of superiority and non-inferiority), number of enrolled patients, response assessment criteria (RECIST or WHO), primary endpoint (central assessed, local assessed or other) and the statistical inference of the primary endpoint according to whether the p value was lower than the probability of the type I error (positive, negative or indeterminate). We also extracted estimated treatment effects from both central and local assessments, including the OR of experimental arm ORR to control arm ORR, OR of experimental arm DCR to control arm DCR, HR of experimental arm PFS to control arm PFS, and HR of experimental arm TTP to control arm TTP. Regarding overlapped data from more than one article on one trial, we selected data based on primarily larger analysis or recently updated analysis. For PFS and TTP, if both intention to treat (or other methods with a larger population) and per-protocol population were available for trials' treatment effects, we preferred the former in our research. According to characteristics, the risk of bias was evaluated in each trial (online [supplementary efigure 1](#SP1){ref-type="supplementary-material"}).
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Statistical analysis {#s2c}
--------------------

First, we investigated whether there were trials with statistically inconsistent inferences between two assessments in primary and secondary endpoints (including ORR, PFS and TTP). If these trials could be identified, we calculated the percentage of these trials among all our eligible trials. Statistically inconsistent inferences are defined as the treatment effect from one of the assessments (eg, central assessment) indicating significant difference (p value is lower than the probability of the type I error or the confidence interval of the treatment effect does not cross 1), but the treatment effect from another assessment (eg, local assessment) indicating non-significant difference (p value is higher than the probability of the type I error, or the confidence interval of the treatment effect crosses 1).

Furthermore, to statistically investigate whether systematic bias existed, we made a comparison of treatment effects between central and local assessments, by conducting a pooling analysis with the inverse variance method and fixed-effect model in Review Manager 5.3 (The Cochrane Collaboration, London, England). In this process, if the corresponding p value for heterogeneity was less than 0.05 or the I^2^ index was over 50%, we used a random-effect model instead of the fixed-effect model in order to reduce the effect of heterogeneity. The pooled OR and HR were the measure of this comparison, expressed as the ratio of central-assessed treatment effects (eg, OR of ORR, OR of DCR, HR of PFS, HR of TTP) to local-assessed treatment effects.[@R11] The OR (of ORR or DCR) greater than 1 indicated that central review overestimated the efficacy of the therapeutic strategy in the experimental arm; while a HR (of PFS or TTP) greater than 1 indicated that central review underestimated the therapeutic efficacy of the experimental arm (compared with local assessment). Regardless of whether the ratio was higher or lower than 1, we concluded no sign of a significant systematic bias if: (1) the corresponding p value was higher than 0.05, which means the 95% CI of the pooled ratio (HR, OR) crossed 1; (2) the 95% CI of the pooled ratio was extremely tight (\<5%) if the first consideration was not met. For the above summary synthesis of ORR, DCR, PFS and TTP, a funnel plot was used to estimate publication bias (online [supplementary efigure 2](#SP2){ref-type="supplementary-material"}). Furthermore, we conducted subgroup analysis based on the trial characteristics: funding source, mask, region, trial design, number of enrolled patients (based on median value of all included trials), tumour type, response assessment criteria, primary endpoint and its outcome, as well as statistical inferences between central and local assessments (consistent/inconsistent).
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In order to verify the result of the pooling analysis, we conducted correlation analysis for the treatment effects between central and local assessments, by using SPSS V.23 (SPSS, Chicago, Illinois, USA). The test for normality was completed first, followed by correlation analysis with a bivariate model: if normal distribution was indicated, we estimated the correlation by the Pearson correlation coefficient; if not, the Spearman's correlation was applied. Significant correlation was indicated when the p value was less than 0.05. The correlation between two assessments was also demonstrated in scatterplots, constructed by using Excel 2011 (Microsoft, Seattle, Washington, USA).

Patient and public involvement {#s2d}
------------------------------

Due to the nature of the literature review, we do not have patient and public involvement in this research.

Results {#s3}
=======

Trial searching and characteristics {#s3a}
-----------------------------------

Based on article identification and selection ([figure 1](#F1){ref-type="fig"}), we included a total of 76 trials from 100 articles, involving 45 688 randomly assigned patients.[@R12]

![Flow chart of study identification and selection. DCR, disease control rate; NCT, National Clinical Trial; ORR, objective response rate; PFS, progression-free survival; RCT, randomised controlled trial; TTP, time to progression.](bmjopen-2017-017240f01){#F1}

Summary and detailed characteristics are presented in [table 1](#T1){ref-type="table"} and in online [supplementary etable 2](#SP8){ref-type="supplementary-material"}. A majority of the 100 articles were published in high-impact journals: *Journal of Clinical Oncology* (29), *Lancet Oncology* (24), *New England Journal of Medicine* (18), *Lancet* (10), *European Journal of Cancer* (4), *Gynecologic Oncology* (4), *Annals of Oncology* (3), *Oncologist* (3) and so on. In all 76 included trials, 15 trials[@R13] reported both central-assessed and local-assessed treatment effects of ORR and DCR; among them, 14 trials[@R13] had those of ORR, DCR and PFS, including one trial[@R68] with those of ORR, DCR, PFS and TTP. Another 12 trials[@R18] with both central and local assessments only contained treatment effects of ORR and PFS.
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###### 

Summary characteristics of included trials

  Characteristics                Trial(s) (n=76)   Patients (n=45 688)
  ------------------------------ ----------------- ---------------------
  Fund source                                      
   Pharmaceutical                73                43 557
   Academic                      3                 2131
  Mask                                             
   Open label                    37                21 455
   Single blind                  1                 185
   Double blind                  38                24 048
  Region                                           
   Global                        62                39 766
   Intracontinental              14                5922
  Design                                           
   Superiority                   71                42 213
   Other\*                       5                 3475
  Number of enrolled patients                      
   Maximum                       --                1314
   Median                        --                542
   Minimum                       --                81
  Tumour type                                      
   Breast cancer                 17                11 132
   NSCLC                         14                9327
   Renal cell carcinoma          11                6720
   Ovarian cancer                6                 4536
   Melanoma                      5                 1675
   Other†                        23                12 298
  Response assessment criteria                     
   RECIST                        71                42 756
   WHO                           4                 2387
   Not given                     1                 545
  Primary endpoint                                 
   Central assessed‡             43                26 344
   Other§                        10                6177
   Local assessed¶               23                13 167
  Primary endpoint outcome                         
   Positive                      51                29 982
   Indeterminate\*\*††           2                 1106
   Negative                      23                14 600

\*Four non-inferiority, one hybrid design combing superiority and non-inferiority.

†Four gastrointestinal stromal tumour, three pancreatic tumour, three sarcoma, three medullary thyroid cancer, two glioblastoma, two prostate cancer, two neuroendocrine tumour, one colorectal adenocarcinoma, one gastric cancer, one head and neck cancer and one hepatocellular carcinoma.

‡Forty central-assessed PFS, two central-assessed time to progression and one central-assessed ORR.

§Nine overall survival and one unknown-assessed ORR.

¶Twenty-three local-assessed PFS.

\*\*One study used ORR as the primary endpoint, but we were unable to recognise which assessment (central or local assessment) for the ORR was considered as the primary endpoint (central-assessed ORR or local-assessed ORR?). Because a significant difference was found in central review (p=0.03) but not found in local assessment (p=0.05), we considered the outcome of the primary endpoint as indeterminate.[@R48]

††Another study considered local-assessed PFS and OS as coprimary endpoints: a significant difference was found in PFS (p\<0.01), but was not found in OS (p=0.10). We considered the outcome of the primary endpoint as indeterminate as well.[@R83]

NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

Statistical analysis {#s3b}
--------------------

### Statistically inconsistent inferences of central and local assessments {#s3b1}

From a total of 76 included trials, 17 trials (22%) had statistically inconsistent inferences (significant difference/non-significant difference) of ORR, PFS and/or TTP between central and local assessments.[@R17] Among these 17 trials, 2 trials[@R29] had inconsistent inferences in both of the primary endpoint and secondary endpoint simultaneously. In total, there were 9 of 17 trials (53%) with significant difference based on central assessment; 5 (56%) of these 9 trials were on open-label design ([table 2](#T2){ref-type="table"}).

###### 

Trials with statistically inconsistent inferences between central and local assessments

  Trial                                                  Endpoint                                       Mask     Tumour type                       Therapy (experimental arm vs control arm)                  HR/OR and p value
  ------------------------------------------------------ ---------------------------------------------- -------- --------------------------------- ---------------------------------------------------------- -----------------------------------------------
  Primary endpoint                                                                                                                                                                                            
   NCT00019682[@R48]                                     ORR                                            Single   Melanoma                          Exp: gp100:209-217(210M)+Montanide ISA-51+interleukin 2    Central: 2.86 (95% CI 1.05 to 7.82); p=0.03
  Con: Interleukin 2                                     Local: 2.33 (95% CI 0.98 to 5.56); p=0.05                                                                                                            
   NCT00471328[@R66]                                     Central PFS                                    Open     Gastrointestinal stromal tumour   Exp: Nilotinib                                             Central: 0.90 (95% CI 0.65 to 1.26); p=0.56
  Con: Best supportive care/BSC+imatinib/BSC+sunitinib   Local: 0.58 (95% CI 0.42 to 0.80); p\<0.01                                                                                                           
   NCT00112294[@R33]                                     Central PFS                                    Open     Non-small-cell lung cancer        Exp: Cetuximab+taxane (paclitaxel/docetaxel)+carboplatin   Central: 0.90 (95% CI 0.76 to 1.07); p=0.24
  Con: Taxane (paclitaxel/docetaxel)+carboplatin         Local: 0.79 (95% CI 0.67 to 0.93); p\<0.01                                                                                                           
   NCT00703326[@R69]                                     Local PFS                                      Double   Breast cancer                     Exp: Ramucirumab+docetaxel                                 Central: 0.79 (95% CI 0.67 to 0.94); p\<0.01
  Con: Placebo+docetaxel                                 Local: 0.88 (95% CI 0.75 to 1.01); p=0.08                                                                                                            
   NCT00391092[@R29]                                     Local PFS                                      Open     Breast cancer                     Exp: Bevacizumab+docetaxel+trastuzumab                     Central: 0.72 (95% CI 0.54 to 0.94); p=0.02
  Con: Docetaxel+trastuzumab                             Local: 0.82 (95% CI 0.65 to 1.02); p=0.08                                                                                                            
   NCT00494299[@R87]                                     Central TTP                                    Double   Hepatocellular carcinoma          Exp: Sorafenib                                             Central: 0.87 (95% CI 0.70 to 1.09); p=0.25
  Con: Placebo                                           Local: 0.79 (95% CI 0.62 to 1.00); p=0.049                                                                                                           
   NCT01007942[@R12]                                     Local PFS                                      Double   Breast cancer                     Exp: Everolimus+trastuzumab+vinorelbine                    Central: 0.88 (95% CI 0.71 to 1.07); p=NG
  Con: Placebo+trastuzumab+vinorelbine                   Local: 0.78 (95% CI 0.65 to 0.95); p\<0.01                                                                                                           
   NCT01584648[@R34]                                     Local PFS                                      Double   Melanoma                          Exp: Trametinib+dabrafenib                                 Central: 0.78 (95% CI 0.59 to 1.04); p=NG
  Con: Placebo+dabrafenib                                Local: 0.75 (95% CI 0.57 to 0.99); p=0.03                                                                                                            
   NCT00412061[@R44]                                     Central PFS                                    Double   Neuroendocrine tumour             Exp: Everolimus+octreotide                                 Central: 0.77 (95% CI 0.59 to 1.00); p=0.03\*
  Con: Placebo+octreotide                                Local: 0.78 (95% CI 0.62 to 0.98); p=0.02\*                                                                                                          
   NCT00056459[@R76]                                     Central PFS                                    Double   Colorectal adenocarcinoma         Exp: Vatalanib+oxaliplatin+fluorouracil+leucovorin         Central: 0.88 (95% CI 0.74 to 1.03); p=0.12
  Con: Placebo+oxaliplatin+fluorouracil+leucovorin       Local: 0.83 (95% CI 0.70 to 0.98); p=0.03                                                                                                            
  Secondary endpoint                                                                                                                                                                                          
   NCT00391092[@R29]                                     ORR                                            Open     Breast cancer                     Exp: Bevacizumab+docetaxel+trastuzumab                     Central: 1.66 (95% CI 1.08 to 2.54); p=0.02
  Con: Docetaxel+trastuzumab                             Local: 1.25 (95% CI 0.82 to 1.92); p=0.30                                                                                                            
   NCT00112294[@R33]                                     ORR                                            Open     Non-small-cell lung cancer        Exp: Cetuximab+taxane(paclitaxel/docetaxel)+carboplatin    Central: 1.67 (95% CI 1.15 to 2.43); p=0.01
  Con: Taxane(paclitaxel/docetaxel)+carboplatin          Local: 1.31 (95% CI 0.92 to 1.86); p=0.13                                                                                                            
   NCT00720941[@R57]                                     ORR                                            Open     Renal cell carcinoma              Exp: Pazopanib                                             Central: 1.35 (95% CI 1.03 to 1.75); p=0.03
  Con: Sunitinib                                         Local: 1.23 (95% CI 0.95 to 1.59); p=0.11                                                                                                            
   NCT01030783[@R79]                                     ORR                                            Open     Renal cell carcinoma              Exp: Tivozanib                                             Central: 1.62 (95% CI 1.10 to 2.39); p=0.01
  Con: Sorafenib                                         Local: 1.23 (95% CI 0.85 to 1.78); p=0.26                                                                                                            
   NCT01523587[@R97]                                     ORR                                            Open     Non-small-cell lung cancer        Exp: Afatinib                                              Central: 2.05 (95% CI 0.98 to 4.29); p=0.06
  Con: Erlotinib                                         Local: 2.88 (95% CI 1.60 to 5.21); p\<0.01                                                                                                           
   NCT01345682[@R105]                                    ORR                                            Open     Head and neck cancer              Exp: Afatinib                                              Central: 1.90 (95% CI 0.88 to 4.14); p=0.10
  Con: Methotrexate                                      Local: 3.00 (95% CI 1.3--6.9); p=0.01                                                                                                                
   NCT00785785[@R110]                                    ORR                                            Open     Gastrointestinal stromal tumour   Exp: Nilotinib                                             Central: 0.71 (95% CI 0.52 to 0.96); p=0.03
  Con: Imatinib                                          Local: 0.78 (95% CI 0.57 to 1.06); p=0.12                                                                                                            
   NCT00388726[@R17]                                     PFS                                            Open     Breast cancer                     Exp: Eribulin                                              Central: 0.87 (95% CI 0.71 to 1.05); p=0.14
  Con: Treatment of physician's choice†                  Local: 0.76 (95% CI 0.64 to 0.90); p\<0.01                                                                                                           
   NCT00449033[@R68]                                     PFS                                            Double   Non-small-cell lung cancer        Exp: Sorafenib+gemcitabine+cisplatin                       Central: 0.96 (95% CI 0.77 to 1.21); p=0.37\*
  Con: Placebo+gemcitabine+cisplatin                     Local: 0.83 (95% CI 0.71 to 0.97); p\<0.01\*                                                                                                         
  TTP                                                                                                                                              Central: 0.91 (95% CI 0.67 to 1.23); p=0.26\*              
                                                         Local: 0.73 (95% CI 0.60to 0.88); p\<0.01\*                                                                                                          

\*One side.

†Any single-agent chemotherapy or hormonal or biological treatment approved for the treatment of cancer.

BSC, best supportive care; central, central assessed; Con, control arm; Double, double blind; Exp, experimental arm; Local, local assessed; NG, not given; Open, open label; ORR, objective response rate; PFS, progression-free survival; Single, single blind; TTP, time to progression.

### Systematic bias between central and local assessments {#s3b2}

All comparison results of pooling analysis are presented at [table 3](#T3){ref-type="table"}. There was no significant difference in the treatment effects of ORR between central and local assessments (OR: 1.02 (95% CI 0.97 to 1.07), p=0.42; heterogeneity: p=0.91, I^2^=0%; online [supplementary efigure 3](#SP3){ref-type="supplementary-material"}). Similarly, no sign of significant difference was in DCR (OR: 0.97 (95% CI 0.92 to 1.03), p=0.32; heterogeneity: p=0.93, I^2^=0%; online [supplementary efigure 4](#SP4){ref-type="supplementary-material"}), PFS (HR: 1.01 (95% CI 0.99 to 1.02), p=0.32; heterogeneity: p=1.00, I^2^=0%; online [supplementary efigure 5](#SP5){ref-type="supplementary-material"}) and TTP (HR: 1.04 (95% CI 0.95 to 1.14), p=0.37; heterogeneity: p=0.59, I^2^=0%; online [supplementary efigure 6](#SP6){ref-type="supplementary-material"}). Subgroup analysis also presented no significant difference between central and local assessments, and no significant interaction effect between different elements of subgroup factors, including open label or blind design ([table 3](#T3){ref-type="table"}).
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###### 

Summary results of comparing treatment effects between central and local assessments

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Summary/subgroup                                               Objective response rate (ORR)   Disease control rate   Progression-free survival                                                                                                                                               
  -------------------------------------------------------------- ------------------------------- ---------------------- --------------------------- ------ ----- ------ --------------------- --------------------- ------ -------- --------------------- -------- --------------------- ------ ----
  Summary                                                        29                              17 949                 1.02 (0.97 to 1.07)         0.42   0%    15     9590                  0.97 (0.92 to 1.03)   0.32   0%       72                    43 695   1.01 (0.99 to 1.02)   0.32   0%

  Funding source                                                                                                                                                                                                                                                                                

   Pharmaceutical                                                28                              17 764                 1.02 (0.97 to 1.07)         0.43   0%    14     9405                  0.97 (0.92 to 1.03)   0.33   0%       69                    41 749   1.01 (0.99 to 1.02)   0.38   0%

   Academic                                                      1                               185                    1.09 (0.61 to 1.95)         0.76         1      185                   0.98 (0.67 to 1.42)   0.91            3                     1946     1.03 (0.95 to 1.11)   0.50   

  Mask                                                                                                                                                                                                                                                                                          

   Open label                                                    23                              14 616                 1.03 (0.98 to 1.09)         0.23   0%    12     7777                  0.96 (0.91 to 1.02)   0.23   0%       36                    20 403   1.01 (0.99 to 1.04)   0.13   0%

   Single blind                                                  1                               185                    1.09 (0.61 to 1.95)         0.76         1      185                   0.98 (0.67 to 1.42)   0.91            --                    --       --                    --     

   Double blind                                                  5                               3148                   0.95 (0.83 to 1.08)         0.41         2      1628                  1.02 (0.89 to 1.17)   0.77            36                    23 292   1.00 (0.98 to 1.02)   0.93   

  Region                                                                                                                                                                                                                                                                                        

   Global                                                        23                              15 384                 1.01 (0.95 to 1.06)         0.81   24%   12     8636                  0.96 (0.91 to 1.02)   0.20   37%      61                    38 714   1.01 (0.99 to 1.02)   0.37   0%

   Intracontinental                                              6                               2565                   1.08 (0.97 to 1.21)         0.17         3      954                   1.11 (0.90 to 1.36)   0.34            11                    4981     1.01 (0.97 to 1.05)   0.68   

  Trial design                                                                                                                                                                                                                                                                                  

   Superiority                                                   27                              15 787                 1.02 (0.97 to 1.08)         0.48   0%    15     9590                  0.97 (0.92 to 1.03)   0.32   --       69                    41 570   1.01 (0.99 to 1.02)   0.34   --

   Other§                                                        2                               2162                   1.03 (0.91 to 1.15)         0.67         --     --                    --                    --              3                     2125     1.01 (0.95 to 1.07)   0.79   

  Number of enrolled\                                                                                                                                                                                                                                                                           
  patients                                                                                                                                                                                                                                                                                      

   \>542                                                         17                              13 260                 1.00 (0.94 to 1.06)         0.94   11%   10     7711                  0.97 (0.91 to 1.03)   0.26   0%       37                    30 493   1.01 (0.99 to 1.03)   0.40   0%

   \<542                                                         12                              4689                   1.06 (0.97 to 1.16)         0.18         5      1879                  1.01 (0.88 to 1.15)   0.93            35                    13 202   1.01 (0.98 to 1.04)   0.60   

  Tumour type                                                                                                                                                                                                                                                                                   

   Breast cancer                                                 6                               4028                   1.08 (0.97 to 1.21)         0.18   0%    5      3435                  0.97 (0.88 to 1.07)   0.58   0%       15                    10 410   1.00 (0.97 to 1.03)   0.88   0%

   NSCLC                                                         8                               5172                   1.01 (0.93 to 1.11)         0.80   3     2063   1.01 (0.89 to 1.13)   0.91                  13     8275     1.02 (0.99 to 1.06)   0.19                                  

   Renal cell carcinoma                                          6                               3917                   1.01 (0.91 to 1.12)         0.81   3     1951   0.95 (0.84 to 1.08)   0.43                  11     6720     1.00 (0.96 to 1.04)   0.87                                  

   Ovarian cancer                                                3                               1985                   0.98 (0.85 to 1.12)         0.72   1     829    0.92 (0.78 to 1.08)   0.31                  6      4536     1.03 (0.99 to 1.09)   0.17                                  

   Melanoma                                                      2                               435                    1.35 (0.91 to 2.00)         0.14   1     185    0.98 (0.67 to 1.42)   0.91                  4      1490     1.02 (0.92 to 1.12)   0.74                                  

   Others¶                                                       4                               2412                   0.99 (0.87 to 1.12)         0.83   2     1127   1.00 (0.84 to 1.19)   1.00                  23     12 264   1.00 (0.97 to 1.03)   0.94                                  

  Response assessment criteria                                                                                                                                                                                                                                                                  

   RECIST                                                        27                              17 088                 1.02 (0.97 to 1.07)         0.55   0%    14     9405                  0.97 (0.92 to 1.03)   0.33   0%       68                    40 948   1.01 (0.99 to 1.02)   0.41   0%

   WHO                                                           2                               861                    1.11 (0.90 to 1.37)         0.33         1      185                   0.98 (0.67 to 1.42)   0.91            3                     2202     1.02 (0.97 to 1.08)   0.44   

   Not given                                                     --                              --                     --                          --           --     --                    --                    --              1                     545      1.00 (0.88 to 1.33)   0.94   

  Primary endpoint                                                                                                                                                                                                                                                                              

   Central assessed                                              17                              11 151                 1.04 (0.98 to 1.10)         0.23   47%   10     6186                  0.97 (0.90 to 1.04)   0.37   0%       40                    24 536   1.01 (0.99 to 1.03)   0.44   0%

   Others\*\*                                                    7                               4465                   0.93 (0.83 to 1.04)         0.19   4     2680   0.98 (0.88 to 1.08)   0.65                  9      5992     1.02 (0.98 to 1.07)   0.26                                  

   Local assessed                                                5                               2333                   1.08 (0.94 to 1.24)         0.27   1     724    0.99 (0.79 to 1.24)   0.95                  23     13 167   1.00 (0.97 to 1.03)   0.96                                  

  Primary endpoint\                                                                                                                                                                                                                                                                             
  outcome                                                                                                                                                                                                                                                                                       

   Positive                                                      19                              11 811                 1.04 (0.98 to 1.11)         0.24   0%    9      5484                  0.99 (0.91 to 1.06)   0.70   0%       50                    28 930   1.00 (0.99 to 1.02)   0.63   0%

   Indeterminate                                                 1                               185                    1.09 (0.61 to 1.95)         0.76   1     185    0.98 (0.67 to 1.42)   0.91                  1      921      0.98 (0.89 to 1.07)   0.65                                  

   Negative                                                      9                               5953                   0.99 (0.92 to 1.07)         0.86   5     3921   0.95 (0.88 to 1.04)   0.29                  21     13 844   1.02 (0.99 to 1.04)   0.24                                  

  Statistical inferences between central and local assessments                                                                                                                                                                                                                                  

   Consistent                                                    18                              10 726                 1.02 (0.96 to 1.09)         0.53   0%    8      5094                  0.95 (0.88 to 1.03)   0.22   0%       56                    32 676   1.00 (0.99 to 1.02)   0.69   0%

   Inconsistent                                                  11                              7223                   1.02 (0.95 to 1.10)         0.60   7     4496   0.99 (0.92 to 1.08)   0.89                  16     11 019   1.02 (0.99 to 1.05)   0.20                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P value for the comparison between central and local assessments.

†I^2^ in summary outcome was for heterogeneity of data synthesis.

‡I^2^ in subgroup was for subgroup difference, representing the interaction effects between the elements of each subgroup factor.

§Four non-inferiority, one hybrid design combing superiority and non-inferiority.

¶Four gastrointestinal stromal tumour, three pancreatic tumour, three sarcoma, three medullary thyroid cancer, two glioblastoma, two prostate cancer, two neuroendocrine tumour, one colorectal adenocarcinoma, one gastric cancer, one head and neck cancer and one hepatocellular carcinoma.

\*\*Nine overall survival and one unknown-assessed ORR.

RECIST, Response Evaluation Criteria in Solid Tumors.

The strength of the correlation between central and local assessments regarding treatment effect of ORR, DCR, PFS and TTP was 0.91 (p\<0.01), 0.93 (p\<0.01), 0.94 (p\<0.01) and 0.90 (p=0.29), respectively ([figure 2](#F2){ref-type="fig"}).

![Scatterplot for the correlation of treatment effects between central and local assessments. DCR, disease control rate; ORR, objective response rate; PFS, progression-free survival; TTP, time to progression.](bmjopen-2017-017240f02){#F2}

Discussion {#s4}
==========

To our knowledge, this is the largest literature review with data analyses investigating blinded independent central review and local assessment in phase III RCTs on solid tumours. Also, it is the first research article to report the statistically inconsistent inferences (significant difference or not) of primary and secondary endpoints assessed by central reviewers and local investigators. We found 22% of trials (17/76) with inconsistent inferences between central and local assessments. However, our subsequent pooling analysis and correlation analysis based on all 76 trials confirmed no sign of systematic bias between central and local assessments, regardless of funding source, mask, region, tumour type, study design, number of enrolled patients, response assessment criteria, primary endpoint and outcome, as well as trials with statistically consistent/inconsistent inferences.

Blinded independent central review is used to detect potential bias introduced by the assessment of local investigators. This consideration is based on a common assumption that local investigators might expect superior efficacy of experimental arm treatments compared with control arm treatments, especially in trials with open-label design. Interestingly, among the 17 trials with statistically inconsistent inferences between central and local assessments, more than half of those 17 studies (9/17; 53%) had a statistically significant difference in central assessment; in these 9 trials, 5 (56%) trials were based on open-label design. This means that central assessment seems to have more positive outcomes in favour of experimental treatments in an open-label design, which contradicts the above common assumption.

With respect to statistically inconsistent inferences between central and local assessments, we assume evaluation variability is one factor accounting for these. As we understand, variability could be impacted by many subjective factors, causing measurement errors or uncertainty.[@R8] This situation occurs when one scan reviewer assesses the response status of different individual patients, as well as when several reviewers conduct the scan assessment for one trial, regardless of whether this is a central or local assessment. In this situation, the evaluation variability attenuates the treatment effect and reduces the statistical power of the clinical trials.[@R6] This understanding has been verified based on 21 phase III cancer trials, demonstrating large variability but no sign of systematic bias between two assessments.[@R112]

Missing data could be another factor. It occurs when some patients do not have complete follow-up to determine progression or death, or when patients stop receiving randomised treatments or use alternative treatments before they have progression.[@R113] In oncological clinical trials, missing data are regarded as censoring. Similar to evaluation variability, the effect of censoring would not contribute to systematic bias but could attenuate the treatment effect.[@R113]

In the trials included in our study, we consider that evaluation variability, censoring and other unmentioned factors simultaneously played a role in attenuating the treatment effects, resulting in statistically inconsistent inferences between two assessments in 17 of the 76 trials. Whereas, regardless of what causes statistically inconsistent inferences, the robustness of the trial efficacy outcome needs to be carefully considered when two assessments present statistically inconsistent inferences, especially in primary endpoint. Even though this inconsistency is unnecessary to reflect a systematic bias, it would be interesting to know how policy-makers consider the approval process for corresponding anticancer agents to the specific patients with cancer.

Considering statistically inconsistent inferences, we believe that blinded independent central review is still a useful method for controlling the risk of bias from local assessment. However, we also question the necessity of central assessment as a routine assessment method for all patients (complete-case fashion) in clinical trials. According to our research, there was no sign of systematic bias: (1) the 95% CIs of all pooled ratios in ORR, DCR, PFS and TTP crossed 1, indicating non-significant difference of the treatment effects between central and local assessments; (2) the 95% CIs were tight as well (especially in PFS), representing quite a precise estimate of the bias that should be negligible. These findings could be further confirmed by our subgroup analysis, even though a small number of the intervals are too wide to be informative due to a limited number of the trials (eg, only one trial used single blind, the OR of ORR was 1.09 (95% CI 0.61 to 1.95)).

When questioning the necessity of the complete central assessment, its drawbacks should be considered as well. First, its implementation in the complete-case fashion is very costly. Second, technically it is hard to conduct a real-time central assessment along with local assessment, to determine disease progression independently. In other words, the decision of central reviewers could be impacted by local investigators when the local investigators declare progression, and 'progressed' patients may start to receive subsequent-line treatments. Therefore, the progression time of these specific patients is unknown for central reviewers, which is called informative censoring.[@R5] Third, based only on imaging information, central reviewers could not conclude progression when patients have symptomatic deterioration. Both information censoring and withdrawal of patients with symptomatic progression (because of no radiological progression in central assessment) may potentially cause bias when the final treatment effects of the experimental arm to the control arm in RCTs are calculated.[@R5] Fourth, similar to local assessment, central assessment also shares some drawbacks, such as evaluation variability, target-lesion selection and different interpretations on non-target or immeasurable lesions.[@R4]

In fact, the continuous implementation of the present response assessment criteria, the RECIST and the WHO criteria, has become controversial in the new era of medicine with biomarker-driven therapies, no matter whether for central or local assessment. For instance, when patients are treated with immunotherapies, some tumour lesions might manifest a sign of tumour 'progression' based on the RECIST/WHO criteria before manifesting a sign of tumour shrinkage, which is called pseudoprogression.[@R115] Pseudoprogression was initially reported by Wolchok et al. They found that by using the immune-related response criteria (irRC), at least 10% of ipilimumab-treated patients whose response status was characterised as progression disease (PD) based on the WHO criteria could have favourable survival.[@R116] The increased lesion in one case of the study was shown by histopathology as T-cell infiltration instead of tumour proliferation when PD was considered according to the WHO criteria.[@R116] Similar findings have been proved by another two studies that compared the assessment of irRC with RECIST V.1.1, and immune-modified RECIST with RECIST V.1.1, respectively.[@R117] Even though in our subgroup analysis the comparison result of central versus local assessments did not present significant difference regardless of the RECIST and WHO criteria, these criteria deserve an improvement for biomarker-driven therapies.

Our research has several limitations. First, due to using data from RCTs with both assessments, our outcome may not perfectly match all phase III trials, especially when the trials are implemented by only one type of assessment. Another situation that needs to be considered is trials evaluating two radiological assessment methods, but eventually reporting the outcomes based only on one assessment in published articles. In this situation, a statistically positive outcome may be reported in one assessment; whereas, the 'not-yet-reported' outcome of another assessment might be negative. Second, we included trials covering all solid tumours instead of focusing on one specific tumour type, in that we assumed that our research outcome could not be strongly impacted by tumours' biological characteristics when comparing specific trial processes (eg, central and local assessments) based on study-level strategy. Our subgroup analysis based on different tumour types verified our assumption.

Furthermore, individual-level data would have been the best option for our research, but we did not have access yet. However, we consider that using study-level data reported in each published article is still a good option because the aim of our research type is to investigate study-level issues. Moreover, given that the effect of informative censoring might exist on the treatment effects of PFS and TTP, we also included another important endpoint, ORR, in order to acquire a more exact understanding about whether the treatment effects of both assessments are consistent or not. In this circumstance, the effect of informative censoring could be eliminated because when assessing ORR, central reviewers and local investigators worked independently before local investigators declared progression. Lastly, even though we have done our best to minimise inconsistency during the process of data extraction, it is possible that potential errors may have accrued. Nevertheless, all reviewers have tried to ensure consistency for data interpretation.

In conclusion, we estimate that there was essentially no systematic bias between local and central assessments, as evidenced by our precisely estimated pooled ratios of OR in ORR and DCR, as well as estimated pooled ratios of HR in PFS and TTP. Despite this, we found that statistically inconsistent inferences could be made in many trials depending on whether central or local assessment was used. Considering these, we think blinded independent central review is still an irreplaceable method for controlling the risk of bias from local assessment, but its routine usage for all patients may be unnecessary in oncological randomised controlled trials.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

This study is the first academic output of the Design, Implementation & Report of Oncological Randomized Controlled Trials (DIRORCT) Research Project, which aims to investigate the quality of RCTs from study design and implementation to final report through systematic review and/or further analysis. We thank Ms Xiaoru Deng (Guangzhou Medical University), Dr Peter Coogan, Professor Joseph T. Steensma, Mr Natalicio Serrano (Brown School at Washington University in St. Louis), Ms Carolyn Smith (The Writing Center at Washington University in St. Louis) for advising article searching and manuscript revision. We also sincerely thank all authors, investigators, sponsors and patients for their effort and participation in our included studies.

JZ, YZ and ST contributed equally.

**Contributors:** JRZ, WHL and JXH conceived and designed the study. JRZ conducted article researching and selection, and quality assessment. JRZ, YYZ and SYT took the lead for data extraction, which was checked by YQC, HRL, DFC, YH, XYW, KXD, SHJ, JQZ, JXX and XZC. JRZ, YYZ, SYT, LJ, QHH, LTH, JXH, ZHX and JYW analysed and interpreted the data. JRZ drafted the manuscript, which was critically revised for important intellectual content by all authors. WHL and JXH supervised the study. All authors, including JRZ, YYZ, SYT, LJ, QHH, LTH, JXH, ZHX, JYW, YQC, HRL, DFC, YH, XYW, KXD, SHJ, JQZ, JXX, XZC, WHL and JXH, have read and approved the final manuscript.

**Funding:** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests:** None declared.

**Patient consent:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** Requests for additional details regarding the study protocol may be made by contacting the author JRZ (jianrong.zhang\@wustl.edu).

**Presented at:** Some data of this research have been presented at ESMO 2016 Annual Meeting.
